185 related articles for article (PubMed ID: 24448396)
21. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers.
Chenoweth MJ; O'Loughlin J; Sylvestre MP; Tyndale RF
Pharmacogenet Genomics; 2013 Apr; 23(4):232-5. PubMed ID: 23462429
[TBL] [Abstract][Full Text] [Related]
22. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Bloom J; Hinrichs AL; Wang JC; von Weymarn LB; Kharasch ED; Bierut LJ; Goate A; Murphy SE
Pharmacogenet Genomics; 2011 Jul; 21(7):403-16. PubMed ID: 21597399
[TBL] [Abstract][Full Text] [Related]
23. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
Mwenifumbo JC; Tyndale RF
Pharmacogenomics; 2007 Oct; 8(10):1385-402. PubMed ID: 17979512
[TBL] [Abstract][Full Text] [Related]
24. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6.
Bloom AJ; Harari O; Martinez M; Madden PA; Martin NG; Montgomery GW; Rice JP; Murphy SE; Bierut LJ; Goate A
Hum Mol Genet; 2012 Jul; 21(13):3050-62. PubMed ID: 22451501
[TBL] [Abstract][Full Text] [Related]
25. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
26. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.
Malaiyandi V; Lerman C; Benowitz NL; Jepson C; Patterson F; Tyndale RF
Mol Psychiatry; 2006 Apr; 11(4):400-9. PubMed ID: 16402128
[TBL] [Abstract][Full Text] [Related]
27. Metabolism and disposition kinetics of nicotine.
Hukkanen J; Jacob P; Benowitz NL
Pharmacol Rev; 2005 Mar; 57(1):79-115. PubMed ID: 15734728
[TBL] [Abstract][Full Text] [Related]
28. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
Kubota T; Nakajima-Taniguchi C; Fukuda T; Funamoto M; Maeda M; Tange E; Ueki R; Kawashima K; Hara H; Fujio Y; Azuma J
Pharmacogenomics J; 2006; 6(2):115-9. PubMed ID: 16402086
[TBL] [Abstract][Full Text] [Related]
29. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Tyndale RF; Sellers EM
Ther Drug Monit; 2002 Feb; 24(1):163-71. PubMed ID: 11805739
[TBL] [Abstract][Full Text] [Related]
30. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
Tricker AR
Toxicology; 2003 Feb; 183(1-3):151-73. PubMed ID: 12504349
[TBL] [Abstract][Full Text] [Related]
31. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI.
Tang DW; Hello B; Mroziewicz M; Fellows LK; Tyndale RF; Dagher A
Neuroimage; 2012 May; 60(4):2136-43. PubMed ID: 22342802
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
Agrawal V; Huang N; Miller WL
Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetics of nicotine metabolism.
Mwenifumbo JC; Tyndale RF
Handb Exp Pharmacol; 2009; (192):235-59. PubMed ID: 19184652
[TBL] [Abstract][Full Text] [Related]
34. A meta-analytic review of the CYP2A6 genotype and smoking behavior.
Carter B; Long T; Cinciripini P
Nicotine Tob Res; 2004 Apr; 6(2):221-7. PubMed ID: 15203795
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.
Chenoweth MJ; Ware JJ; Zhu AZX; Cole CB; Cox LS; Nollen N; Ahluwalia JS; Benowitz NL; Schnoll RA; Hawk LW; Cinciripini PM; George TP; Lerman C; Knight J; Tyndale RF;
Addiction; 2018 Mar; 113(3):509-523. PubMed ID: 28921760
[TBL] [Abstract][Full Text] [Related]
36. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.
Ray R; Tyndale RF; Lerman C
J Neurogenet; 2009; 23(3):252-61. PubMed ID: 19169923
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of 7-ethoxycoumarin, safrole, flavanone and hydroxyflavanone by cytochrome P450 2A6 variants.
Uno T; Obe Y; Ogura C; Goto T; Yamamoto K; Nakamura M; Kanamaru K; Yamagata H; Imaishi H
Biopharm Drug Dispos; 2013 Mar; 34(2):87-97. PubMed ID: 23112005
[TBL] [Abstract][Full Text] [Related]
38. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL
Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205
[TBL] [Abstract][Full Text] [Related]
39. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Malaiyandi V; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
[TBL] [Abstract][Full Text] [Related]
40. Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries.
Baurley JW; Edlund CK; Pardamean CI; Conti DV; Krasnow R; Javitz HS; Hops H; Swan GE; Benowitz NL; Bergen AW
Nicotine Tob Res; 2016 Sep; 18(9):1837-1844. PubMed ID: 27113016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
